Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update
September 13, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
– Company expects to report top-line data from China pivotal trial for lead drug candidate CBP-201 in atopic dermatitis in October 2022 – – Company to Host Conference Call Today at 4:30 p.m. ET – ...
Connect Biopharma to Report First Half 2022 Financial Results on September 13
September 01, 2022 08:00 ET
|
Connect Biopharma Holdings Limited
Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT SAN DIEGO and TAICANG, SUZHOU, China, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB)...
Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study
August 30, 2022 08:00 ET
|
Connect Biopharma Holdings Limited
– CBP-174 in development for pruritus associated with allergic and inflammatory skin diseases, including atopic dermatitis, was observed to be safe and well-tolerated – SAN DIEGO and TAICANG, SUZHOU,...
Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022
July 11, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled — — Expected Timing for Potential NDA Approval in China Remains Unchanged and is Targeted for 2025 — SAN DIEGO and...
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
June 17, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, SUZHOU, China, June 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”) announced on June 16, 2022,...
Connect Biopharma to Participate at the Jefferies Healthcare Conference
June 02, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, SUZHOU, China, June 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage...
Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference
May 17, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, China, May 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical...
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
May 03, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
Primary endpoint of change from baseline on adapted Mayo Score for CBP-307 0.2 mg once-daily, orally administered dose showed a numerical improvement, but did not achieve statistical significance...
Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update
March 31, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
- Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 -- Topline Phase 2 CBP-307 Results in Moderate-to-Severe Ulcerative Colitis Expected to Be...
Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer
March 01, 2022 08:00 ET
|
Connect Biopharma Holdings Limited
CMO appointment to propel Connect through clinical milestones across solid pipeline of inflammatory disease therapies in development SAN DIEGOand TAICANG, China, March 01, 2022 (GLOBE NEWSWIRE) --...